15q13.3 microdeletion syndrome

15q13.3 microdeletion syndrome (also known as chromosome 15q13.3 deletion syndrome) is a rare genetic condition caused by a small deletion of genetic material on the long arm of chromosome 15, typically spanning approximately 1.5 to 2 megabases in the 15q13.2-q13.3 region. This deletion most commonly encompasses the CHRNA7 gene, which encodes a neuronal nicotinic acetylcholine receptor subunit important for brain function. The syndrome primarily affects the nervous system and is associated with a wide spectrum of clinical severity, ranging from apparently normal individuals to those with significant neurodevelopmental impairment. Key clinical features include intellectual disability (which is often mild to moderate), learning difficulties, speech and language delays, epilepsy or seizures, and behavioral problems including autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), and aggressive behavior. Some individuals may also exhibit mild dysmorphic facial features, hypotonia (low muscle tone), and psychiatric manifestations such as mood disorders or schizophrenia. Notably, the clinical presentation is highly variable, and some carriers of the deletion may be clinically unaffected, which reflects the reduced penetrance associated with this condition. There is currently no cure or specific targeted therapy for 15q13.3 microdeletion syndrome. Management is symptomatic and supportive, tailored to the individual's specific needs. This may include antiepileptic medications for seizure control, speech and occupational therapy, behavioral interventions, special educational support, and psychiatric treatment when indicated. Early intervention programs are recommended to optimize developmental outcomes. Genetic counseling is important for affected families, particularly given the variable expressivity and incomplete penetrance of this deletion.

Common questions about 15q13.3 microdeletion syndrome